Ciclesonide
Active ingredient · 2 therapeutic classes
Sold as ALVESCO · OMNARIS
- Drug class
- Glucocorticoids
- Availability
- Prescription only
- Routes
- Nasal, Inhalation
- Markets covered
- 3
- Products on record
- 35
- FDA reports (12 mo)
- 744
Overview
Plain-language summary, compiled from the cited regulatory records
Ciclesonide is a corticosteroid medication [1]. It is approved for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older [1]. It is also indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older [1].
Ciclesonide is available under various brand names, including Omnaris [1]. In the past 12 months, there have been 744 adverse event reports associated with this active ingredient [2]. The most frequently reported adverse events include asthma, wheezing, dyspnoea, therapeutic product effect incomplete, and cough [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 31 | April 10, 2026 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
| US United States | FDA | 1 | November 8, 2022 |
GBUnited Kingdom· MHRA
31 products
Uses
Ciclesonide Advanz Pharma is indicated in treatment to control persistent asthma in adults and adolescents (12 years and older).
How to take
CACanada· Health Canada
3 products
Uses
AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................. 3 WARNINGS AND PRECAUTIONS ...............................................................................
4 ADVERSE REACTIONS ................................................................................................. 8 DRUG INTERACTIONS ...............................................................................................
12 DOSAGE AND ADMINISTRATION ........................................................................... 13 OVERDOSAGE .............................................................................................................. 15 ACTION AND CLINICAL PHARMACOLOGY ..........................................................
15 STORAGE AND STABILITY ....................................................................................... 18 DOSAGE FORMS, COMPOSITION AND PACKAGING........................................... 18 PART II: SCIENTIFIC INFORMATION..............................................................................
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE OMNARIS Nasal Spray is a corticosteroid indicated for treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
1 Treatment of Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 2 Treatment of Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older.
How to take
Drug interactions
Known interactions involving Ciclesonide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB567340012 · revised April 10, 2026
- [2]Health Canada (DPD) · 02285606 · revised March 22, 2025
- [3]FDA DailyMed · 15fefd46-ac7e-40… · revised November 8, 2022 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.